Molecular diagnosis of Sentinel Lymph Node Biopsy in Early-stage Cervical Cancer

Study of Sentinel Lymph Node Biopsy for Assessing the Pelvic Nodal Status in Early-stage Cervical Cancer

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DDT-13004052

Enrollment

Unknown

Registered

2013-05-20

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Gold Standard:

Index test:

Eligibility

Sex/Gender

Female

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. early-stage cervical cancer (FIGO stage IA2 to IIA); 2. All women who participated in the study provided written informed consent; 3. Patients are going to receive systematic pelvic lymphadenectomy.

Exclusion criteria

Exclusion criteria: 1. lymph node metastasis detected by CT; 2. medical history of subtotal hysterectomy; 3. allergic history of 99mTechnetium-labeled sulfur colloid or Methylthioninium chloride.

Design outcomes

Primary

Measure	Time frame
Sentinel lymph node metastasis;	—

Countries

China

Contacts

Public ContactXiugui Sheng

Shandong Cancer Hospital and Institute

jnsxg@hotmail.com+86 13608921932

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026